"230950" . "14110" . . . "1801-1209" . "I" . "RIV/00216224:14110/11:00055523!RIV12-MSM-14110___" . . "P\u0159\u00EDchod antiemetik ze skupiny inhibitor\u016F 5-HT3-receptor\u016F p\u0159ed dv\u011Bma desetilet\u00EDmi se stal v\u00FDznamn\u00FDm p\u0159\u00EDnosem pro antiemetickou profylaxi, ale sou\u010Dasn\u011B vytvo\u0159il klamn\u00E9 zd\u00E1n\u00ED, \u017Ee probl\u00E9m nevolnosti a zvracen\u00ED po chemoterapii byl t\u00EDmto vy\u0159e\u0161en. P\u0159esto\u017Ee byly vypracov\u00E1ny a jsou pravideln\u011B aktualizov\u00E1ny mezin\u00E1rodn\u011B uzn\u00E1van\u00E9 standardn\u00ED postupy, jak t\u011Bmto ne\u017E\u00E1douc\u00EDm \u00FA\u010Dink\u016Fm chemoterapie p\u0159edch\u00E1zet, v praxi st\u00E1le z\u016Fst\u00E1vaj\u00ED v\u00FDznamn\u00E9 rezervy v jejich uplat\u0148ov\u00E1n\u00ED. Jednou z p\u0159\u00ED\u010Din je podhodnocov\u00E1n\u00ED re\u00E1ln\u00E9ho v\u00FDskytu t\u011Bchto obt\u00ED\u017E\u00ED i z\u00E1va\u017Enosti, jakou zejm\u00E9na z pohledu pacient\u016F maj\u00ED. V b\u011B\u017En\u00E9 praxi dosud nen\u00ED dostate\u010Dn\u011B vyu\u017E\u00EDv\u00E1no v\u00FDhod kombinace inhibitor\u016F 5-HT3-receptor\u016F s dexamethasonem, p\u0159esto\u017Ee v\u011Bdeck\u00E9 doklady pro jej\u00ED \u00FA\u010Dinnost jsou p\u0159esv\u011Bd\u010Div\u00E9. Nov\u00E1 antiemetika, zejm\u00E9na palonosetron a aprepitant, d\u00E1le roz\u0161i\u0159uj\u00ED na\u0161e mo\u017Enosti \u00FA\u010Dinn\u00E9 terapie, je v\u0161ak t\u0159eba pou\u017E\u00EDvat je profylakticky od prvn\u00EDho cyklu emetogenn\u00ED onkologick\u00E9 l\u00E9\u010Dby v souladu se sou\u010Dasn\u00FDmi standardn\u00EDmi doporu\u010Den\u00EDmi." . "8"^^ . . . . . . . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k prevenci a l\u00E9\u010Db\u011B nevolnosti a zvracen\u00ED p\u0159i chemoterapii"@cs . "[D88B8C1EABBA]" . "P\u0159\u00EDchod antiemetik ze skupiny inhibitor\u016F 5-HT3-receptor\u016F p\u0159ed dv\u011Bma desetilet\u00EDmi se stal v\u00FDznamn\u00FDm p\u0159\u00EDnosem pro antiemetickou profylaxi, ale sou\u010Dasn\u011B vytvo\u0159il klamn\u00E9 zd\u00E1n\u00ED, \u017Ee probl\u00E9m nevolnosti a zvracen\u00ED po chemoterapii byl t\u00EDmto vy\u0159e\u0161en. P\u0159esto\u017Ee byly vypracov\u00E1ny a jsou pravideln\u011B aktualizov\u00E1ny mezin\u00E1rodn\u011B uzn\u00E1van\u00E9 standardn\u00ED postupy, jak t\u011Bmto ne\u017E\u00E1douc\u00EDm \u00FA\u010Dink\u016Fm chemoterapie p\u0159edch\u00E1zet, v praxi st\u00E1le z\u016Fst\u00E1vaj\u00ED v\u00FDznamn\u00E9 rezervy v jejich uplat\u0148ov\u00E1n\u00ED. Jednou z p\u0159\u00ED\u010Din je podhodnocov\u00E1n\u00ED re\u00E1ln\u00E9ho v\u00FDskytu t\u011Bchto obt\u00ED\u017E\u00ED i z\u00E1va\u017Enosti, jakou zejm\u00E9na z pohledu pacient\u016F maj\u00ED. V b\u011B\u017En\u00E9 praxi dosud nen\u00ED dostate\u010Dn\u011B vyu\u017E\u00EDv\u00E1no v\u00FDhod kombinace inhibitor\u016F 5-HT3-receptor\u016F s dexamethasonem, p\u0159esto\u017Ee v\u011Bdeck\u00E9 doklady pro jej\u00ED \u00FA\u010Dinnost jsou p\u0159esv\u011Bd\u010Div\u00E9. Nov\u00E1 antiemetika, zejm\u00E9na palonosetron a aprepitant, d\u00E1le roz\u0161i\u0159uj\u00ED na\u0161e mo\u017Enosti \u00FA\u010Dinn\u00E9 terapie, je v\u0161ak t\u0159eba pou\u017E\u00EDvat je profylakticky od prvn\u00EDho cyklu emetogenn\u00ED onkologick\u00E9 l\u00E9\u010Dby v souladu se sou\u010Dasn\u00FDmi standardn\u00EDmi doporu\u010Den\u00EDmi."@cs . . "CZ - \u010Cesk\u00E1 republika" . . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k prevenci a l\u00E9\u010Db\u011B nevolnosti a zvracen\u00ED p\u0159i chemoterapii"@cs . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k prevenci a l\u00E9\u010Db\u011B nevolnosti a zvracen\u00ED p\u0159i chemoterapii" . . "7" . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k prevenci a l\u00E9\u010Db\u011B nevolnosti a zvracen\u00ED p\u0159i chemoterapii" . "1"^^ . . . "Current approaches to prevention and treatment of nausea and vomiting during chemotherapy"@en . "The advent of 5-HT3 receptor inhibitors two decades ago became an important contribution to antiemetic prophylaxis but led to false idea that the problem of nausea and vomiting after chemotherapy has been solved. Despite of elaborated international guidelines for antiemesis significant reserve continues to apply them in clinical practice. Underestimation of real nausea and vomiting occurrence and their impact on patients are among reasons. Advantages of 5-HT3 receptor inhibitors combined with dexamethasone have not been fully employed despite of available convincing evidence. New antiemetics, especially palonosetron and aprepitant, further extend our potential of effective therapy, but it is necessary to use them in prophylaxis from the first course of emetogenic anticancer treatment according to guidelines."@en . "Farmakoterapie" . "1"^^ . "2" . "RIV/00216224:14110/11:00055523" . . "Tom\u00ED\u0161ka, Miroslav" . . "Current approaches to prevention and treatment of nausea and vomiting during chemotherapy"@en . "nausea and vomiting; chemotherapy; aprepitant; palonosetron"@en .